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Abstract
Isoprenoids are natural products that are all derived from isopentenyl diphosphate (IPP) and dimethylallyl diphosphate
(DMAPP). These precursors are synthesized either by the mevalonate (MVA) pathway or the 1-Deoxy-D-Xylulose 5-
Phosphate (DXP) pathway. Metabolic engineering of microbes has enabled overproduction of various isoprenoid products
from the DXP pathway including lycopene, artemisinic acid, taxadiene and levopimaradiene. To date, there is no method to
accurately measure all the DXP metabolic intermediates simultaneously so as to enable the identification of potential flux
limiting steps. In this study, a solid phase extraction coupled with ultra performance liquid chromatography mass
spectrometry (SPE UPLC-MS) method was developed. This method was used to measure the DXP intermediates in
genetically engineered E. coli. Unexpectedly, methylerythritol cyclodiphosphate (MEC) was found to efflux when certain
enzymes of the pathway were over-expressed, demonstrating the existence of a novel competing pathway branch in the
DXP metabolism. Guided by these findings, ispG was overexpressed and was found to effectively reduce the efflux of MEC
inside the cells, resulting in a significant increase in downstream isoprenoid production. This study demonstrated the
necessity to quantify metabolites enabling the identification of a hitherto unrecognized pathway and provided useful
insights into rational design in metabolic engineering.
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Introduction
Isoprenoids are a large family of compounds (more than 55,000)
comprising numerous products used as fragrances, insecticides,
nutraceuticals and pharmaceuticals [1,2]. Supply of these mole-
cules has been limited by scarce plant resources from which they
were originally extracted. Production by chemical synthesis is
uneconomical due to the complex structure of these products [1].
Microbial metabolic engineering has been intensively explored in
the past decade for isoprenoid production and gram per liter
production levels has been achieved for certain isoprenoid
precursors [3].
Despite the structural diversity of isoprenoids, they are all
derived from isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMAPP). Both metabolites are synthesized either by
the mevalonate (MVA) pathway or the 1-Deoxy-D-Xylulose 5-
Phosphate (DXP) pathway (Figure 1) [4]. Engineering of the DXP
pathway (also known as MEP pathway) in Escherichia coli (E. coli)
results in significant increase in the biosynthesis of IPP/DMAPP
[3,5]. Four enzymes in the DXP pathway (dxs, idi, ispD and ispF)
were identified combinatorially to be rate limiting [6] and
overexpressions of the genes encoding these enzymes were
empirically optimized to maximize isoprenoid yields. It is also
known that excessive overexpression of these enzymes can inhibit
isoprenoid production [3,7,8,9,10]. Recently, we demonstrated
that strong overexpression of metabolic enzymes (dxs, idi, ispD
and ispF) did not affect the expression of isoprenoid transcripts
which was hypothesized to contribute to the decrease in lycopene
production [11]. To better understand the mechanisms underlying
the inverse correlation of lycopene production with overexpression
of the DXP genes, a direct measurement of the metabolites is
desirable.
Quantification of the metabolites of the heterologous mevalo-
nate pathway in engineered E. coli allowed the identification of
pathway limiting steps and generated rational gene targets for
circumventing production inhibition [12]. Attempts have been
made previously to measure methylerythritol cyclodiphosphate
(MEC), a metabolite of the DXP pathway, in cell extracts using a
semi-quantitative and labor intensive method involving 31P-NMR
[13]. DMAPP and IPP, products of the DXP and MVA pathways,
have also been previously quantified by mass-spectrometry
[14,15]. As yet, there is no direct method to simultaneously
quantify all DXP pathway metabolic intermediates (Figure 1).
To address the unmet need of a method for the simultaneous
quantification of DXP metabolites, we have developed an
integrated preanalytical solid phase extraction (SPE) procedure
with the use of ultra performance liquid chromatography mass
spectrometry (UPLC-MS). The SPE procedure exploits the unique
physiocochemical properties of the DXP intermediates to selec-
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tively enrich these compounds from biological samples. The
performance of this SPE coupled UPLC-MS protocol was then
demonstrated with synthetic standards in E. coli extracts, and was
found to be superior in analytical sensitivity and ease-of-use. With
the developed method, MEC was found to be unexpectedly
effluxed from E. coli, by yet to be characterized mechanisms, which
significantly reduced the production of isoprenoids. The overex-
pression of ispG was predictably found to result in lower MEC
efflux and increased isoprenoid production. This study has
developed invaluable tools for rational engineering of the DXP
pathway for overproduction of isoprenoids.
Results
UPLC-MS analysis of the DXP pathway intermediate
standards
In the DXP pathway (Figure 1), pyruvate (PYR) and
glyceraldehyde 3-phosphate (GAP) are first condensed by dxs
with thiamine to produce 1-deoxy-D-xylulose 5-phosphate (DXP)
[4]. DXP is then reduced and isomerized by a single enzyme dxr
with NADPH to form 2C-methyl-D-erythritol 4-phosphate (MEP)
[4]. MEP reacts with CTP in the presence of ispD to produce 4-
diphosphocytidyl-2C-methyl D-erythritol (CDP-ME) [4]. CDP-
ME is phosphorylated by an ATP dependent kinase ispE to form
4-diphosphocytidyl-2C-methyl D-erythritol 2-phosphate (CDP-
MEP) [4]. CMP is eliminated from CDP-MEP and the molecule
is cyclized by ispF to form 2C-methyl-D-erythritol 2,4-diphosphate
(MEC) [4]. The ring structure of MEC is opened and reduced by
an iron-sulfur cluster containing enzyme ispG by a yet to be fully
characterized mechanism to form hydroxylmethylbutenyl diphos-
phate (HMBPP) [16]. HMBPP is further reduced by another iron-
sulfur cluster containing enzyme ispH, to produce a mixture of
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate
(DMAPP) [17]. Unlike the mevalonate pathway, all the DXP
intermediates are phosphorylated and highly acidic. This unique
physicochemical property allowed a single step purification of all
these metabolites using anionic SPE.
Attempts were initially made to quantify the DXP pathway
intermediates by gas chromatography mass spectrometry (GC-
MS) after derivatization with trimethylsilyl (TMS). DXP and MEP
were readily detected (limit of detection at least 9 pmol per
injection). However, all other DXP intermediates were not
detectable, likely to be due to the low volatility of the TMS
derivatives (File S1). We next explored ultraperformance liquid
chromatography mass spectrometry (UPLC-MS) for the quanti-
fication of the DXP pathway intermediates.
A time-of-fight mass spectrometry was selected because it has
the highest scan speed and excellent mass accuracy as compared to
other types of mass spectrometry [18]. A range of mass-to-charge
ratio (m/z) was scanned in the negative mode and synthetic
standards were characterized. All DXP pathway intermediates can
be detected and their m/z were unambigously determined
(Table 1). Separation of the DXP pathway intermediates was
then optimized on a UPLC C18 column (1.7 mm particle size). Ion
pairing with tributylamine was found to be an ideal ion-pair
reagent allowing excellent resolutions of the various intermediates
rapidly (10 mins per sample; Table 2; Figure 2).
Development of solid phase extraction
Solid phase extraction (SPE) has been widely used to isolate
analytes in various biological samples [19,20,21]. It is rapid and
can enrich analytes under mild conditions without the need for
solvent evaporation from the extracts [15]. As all the DXP
intermediates of interest are phosphorylated (Figure 1), we
explored the use of anion exchange SPE [22]. The direct SPE
recoveries of all the intermediates were .40% as compared to the
initial concentrations of standards used (File S2). It is worthy to
note that the LC-NH2 resin used in this study was superior in
performance when compared to other similar supports (data not
shown) [22].
To examine the linearity, dynamic range and limit of
quantification (LOQ) of the SPE UPLC-MS analysis for the
DXP pathway intermediates in cell extracts, mixture of DXP,
MEP, CDP-ME, CDP-MEP (in house synthesized), MEC, and
HMBPP were spiked into 10 mL of cell extracts to final
Figure 1. Metabolites and enzymes related to the 1-Deoxy-D-xylulose 5-Phosphate pathway.
doi:10.1371/journal.pone.0047513.g001
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concentrations ranging from 2 mM to 0.01 mM. The extracts were
then loaded onto an SPE cartridge and eluted in ammonium
hydroxide. The results showed that the UPLC-MS signals of all
intermediates were linearly correlated with the initial concentra-
tions in cell extracts (R2.0.99). In addition, the method
demonstrated the LOQ (LOQ#0.1 mM), intraday variation and
interday variations (CV,12%) allowing precise quantification of
the DXP pathway intermediates in biological samples (Table 1).
With the developed method, though LOQ of CDP-MEP
(0.1 mM) was much higher than that of the other metabolites
examined (0.01 mM), it was still considerably more sensitive than
reported for the quantification of mevalonate metabolites (a similar
class of compounds to DXP metabolites) at LOQ of 4.17 mM [15].
CDP-MEP was found to be co-eluted with many major cellular
phospho-compounds, which is likely to result in lower signal due to
the phenomenon of ion suppression (File S3). Nonetheless, most
these intermediates were readily detected in the genetically
modified strains relevant to metabolic engineering of the DXP
pathway.
Analysis of a lycopene producing E. coli
Lycopene is an antioxidant isoprenoid and the production in E.
coli is known to be enhanced by overexpression of four enzymes in
the DXP pathway (dxs, idi, and ispDF) under non-induced
conditions [11]. Consistent with previous studies [3,8], the strong
overexpression of four enzymes (dxs, idi, ispD and ispF) resulted in
the inhibition of lycopene production (Figure 3 B). To analyze the
profiles of DXP pathway intermediates under this condition, cells
were harvested in the exponential phase and the metabolites were
quantified. Four intermediates (DXP, MEP, CDP-ME and MEC)
were detected in all treatments, and the concentrations increased
in parallel to the amounts of inducers, IPTG (Figure 3 C).
Interestingly, a significant decrease of intracellular MEC concen-
tration was observed with 0.1 mM IPTG induction (Figure 3 C).
Further analysis detected the accumulation of large amount of
MEC in the growth medium, greater than the total amount found
in the cellular fraction (Figure 3 D). This was an unexpected and
intriguing observation as highly charged, phosphorylated com-
pounds, are not known to passively diffuse across intact cell
membrane. Similar growth curves were observed with or without
0.1 mM IPTG induction (Figure 3 A), indicative that the viabilities
of the cells were not observably different. The high accumulation
of MEC in the broth thus could be selectively effluxed from the
cells. Preliminary studies showed that the fsr efflux pump may be
involved in this process (File S4). It is then not unreasonable to
speculate that MEC accumulates to an intracellular threshold
concentration (,30 mmol/L, Figure 3 C) resulting in cellular stress
response, as suggested by a recent study of MEC in response to
oxidative stress [23]. This may in turn result in the efflux of MEC
so as to prevent further intracellular accumulation of this
metabolite.
Although the exogenous addition of MEC to levels similar to the
amounts effluxed did not affect cell growth and lycopene
production (File S5), efflux of MEC itself may have diverted
carbon source away from biosynthesis of isoprenoid products
resulting in the decrease in isoprenoid biosynthesis. The good
inverse correlation between lycopene production and the concen-
tration of extracellular MEC at various IPTG inductions was
consistent with this suggestion (Figure 3 B and D).
Rational engineering of the DXP pathway in E. coli for
lycopene production
To test whether lycopene production inhibition was related to
MEC efflux, the strain was engineered to co-overexpress ispG
(with dxs-idi-ispDF), the enzyme utilizing MEC (Figure 1). In the
strong induction condition (0.1 mM IPTG), where lycopene
production was severely inhibited and MEC efflux was high
(Figure 3 B and D), co-overexpression of ispG indeed concurrently
increased lycopene production (Figure 4 A) and reduced efflux of
MEC (Figure 4 B). The concentration of intracellular MEC was
found to be increased with ispG overexpression, a result
Table 1. Analytical performance of the SPE UPLC-MS method.
Compound
Retention time
(mins)
Quantification ions
[M -H]2 Linearity LOQ (mM) Repeatability (0.1 mM)*
Range (mM) R2
Intraday
variation
(n=5, CV%)
Interday
variation (n =4,
CV%)
DXP 5.6 213.017060.03 0.01–2 0.9934 0.01 6.85 7.71
MEP 5.2 215.0330+0.01–0.03 0.01–2 0.9956 0.01 4.69 7.83
CDP-ME 6.2 520.073060.03 0.01–0.5 0.9941 0.01 3.90 7.62
CDP-MEP 7.3 600.039060.03 0.1–1 0.9902 0.1 10.91 11.63
MEC 6.6 276.988460.03 0.02–2 0.9991 0.02 6.20 5.63
HMBPP 7.0 260.992060.03 0.01–2 0.9959 0.01 6.54 9.97
*Concentration of CDP-MEP for intra-day/inter-day variation was 0.25 mM.
doi:10.1371/journal.pone.0047513.t001
Table 2. Mobile phase gradient used for the separation of
DXP intermediates in the UPLC method.
Step Time (mins)
Aqueous
solution* Methanol
1 0 100% 0
2 1.8 100% 0
3 3.1 60% 40%
4 4.9 60% 40%
5 5.4 10% 90%
6 9.5 10% 90%
7 10 100% 0
*Aqueous solution: 15 mM acetic acid and 10 mM tributylamine.
doi:10.1371/journal.pone.0047513.t002
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supporting the proposal of an intimate relationship between ispG
and intracellular MEC. HMBPP (a product of ispG, Figure 1) was
also readily detected inside the cells overexpressing ispG (HMBPP
was not detectable in the parental strain expressing dxs-idi-ispDF,
Figure 4 D), consistent with the above proposal that with higher
ispG more MEC was consumed for isoprenoid biosynthesis. In
order to gain an insight into the profiles of efflux pumps in these
strains, all the 20 known efflux pump operons in E. coli [24] were
analyzed at the transcription level. The expression levels of these
pumps were not regulated by ispG overexpression (Figure 5).
Taken together, overexpression of the metabolic enzyme ispG
reduced the amount of MEC efflux possibly by shuttling it directly
to the downstream products, e.g. lycopene.
Analysis of bacteria other than E. coli
To demonstrate the broader utility of the method developed
here, measurements of the DXP metabolites were conducted in
other bacteria. Besides E. coli, other bacteria have also been used
for the production of isoprenoids [25]. The DXP metabolites of
two gram negative strains (Chromobacterium violaceum [26] and
Pseudomonas aeruginosa [27]) and one gram positive strain (Bacillus
subtilis [25]) were characterized. A gram positive strain (Staphylo-
coccus aureus [28]) that utilize the MVA pathway but not the DXP
pathway was also included as a negative control. Analysis of the
cells harvested in the exponential growth phase (OD595= 2–3)
indeed showed that intracellular DXP pathway intermediates can
be detected in all strains except Staphylococcus aureus (Figure 6). The
four bacteria used in this study were all wild types, where the DXP
pathway genes were not genetically overexpressed. The level of the
DXP pathway intermediates in these strains was expectedly lower
than that in engineered E. coli, yet the developed method here has
the sensitivity to measure these intermediates. None of the DXP
pathway intermediates were detected in the broth supernatant of
these strains (data not shown), suggesting that no DXP interme-
diates were effluxed from these cells under the conditions.
Figure 2. Effects of UPLC gradient on chromatography separation of the DXP pathway intermediates. Different concentrations (0.8, 0.4,
2.6, 2.6, 0.5 and 2 mM respectively) of DXP, MEP, CDP-ME, CDP-MEP, MEC, and HMBPP were prepared in 1 mL acidic extraction solution and purified as
described in METHODS AND MATERIALS. Quantification m/z ratio for each compound was extracted from total ion chromatography as Table 1 and
traces were overlaid. (A) UPLC gradient described was employed as Table 2 except 40% aqueous solution was used in step 3 and 4; (B) UPLC gradient
described was employed as Table 2 except 50% aqueous solution was used in step 3 and 4; (C) UPLC gradient described was employed as Table 2; (D)
UPLC gradient described was employed as Table 2 except 70% aqueous solution was used in step 3 and 4; (E) UPLC gradient described was employed
as Table 2 except 80% aqueous solution was used in step 3 and 4.
doi:10.1371/journal.pone.0047513.g002
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Discussion
The engineered DXP pathway has been demonstrated to be a
powerful synthetic platform for microbial production of valuable
isoprenoids. However, current strategies in manipulation of this
pathway are still mostly combinatorial in nature, which are largely
due to the lack of methods for conveniently monitoring changes of
the pathway in metabolite level. Although a LC-MS/MS method
was recently reported for measuring some of the DXP metabolites
[29], a more sensitive and convenient method was still desirable
because the LC-MS/MS method had moderate sensitivities
(,5 mM for most metabolites) and involved liquid-liquid extrac-
tion in sample preparation. In this study, the use of UPLC-MS, for
the first time, has enabled the detection of all the DXP
metabolites. Coupled to an anion exchange solid phase extraction
protocol, the method was able to quantify all the DXP metabolites
in biological samples with good sensitivity (LOQ#0.1 mM) and
reliability (intraday variation CV#12%). Sample preparation in
our method was also rapid (5 mins) and easy (drying free),
demonstrating the superiority of the SPE UPLC-MS method
developed in this study. In the analyzed biological samples, all the
DXP metabolites except CDP-MEP were detected (Figure 3 C
and Figure 4 D). A strain overexpressing dxs and ispE (the enzyme
to produce CDP-MEP) was constructed for the purpose of
demonstration in quantifying the amount of endogenous CDP-
MEP. However, the metabolite was still undetectable. It is likely
that ispE and ispF formed protein complex in E. coli [30] and
consumed most CDP-MEP once it was produced.
Beyond the method development, this study has also signifi-
cantly contributed to the body of knowledge of the DXP
metabolism in isoprenoid production. In the engineered lycopene
producing E. coli, MEC was found to be actively effluxed, serving
as a previously unrecognized branch in the DXP pathway.
Kinetics of this competing branch pathway was estimated by
inhibiting MEC synthesis with fosmidomycin and measuring the
amounts of accumulated intracellular MEC. It was found that a
portion of the accumulated MEC was actually effluxed within
2 hours instead of being utilized by the cells (Figure 7), indicative
that MEC efflux served as a competing pathway diverting carbon
source away from the isoprenoid biosynthesis (consistent with the
inverse correlation between Figure 3 B and D). From a theoretical
consideration, the amounts of MEC accumulated in the media at
24 h after induction was ,220 mmol/L (Figure 4 B), which was
calculated to be equivalent to 4500 ppm lycopene and significantly
greater than the amount of lycopene produced (1000 ppm,
Figure 4 A). As a rational strategy, ispG was then overexpressed
and the efflux of MEC was successfully reduced, resulting in the
increase of the downstream intermediates (HMBPP etc.) and the
isoprenoid product (lycopene). These findings have demonstrated
the usefulness of the developed SPE UPLC-MS method. Future
studies to effectively divert the amount of MEC effluxed into
isoprenoid biosynthesis will invariably be valuable to the
engineering of microbes for the overproduction of isoprenoids.
Figure 3. Analysis of E. coli expressing DXP pathway genes. E. coli BL21-Gold (DE3) harboring pACLYC and pET-SIDF was induced
with IPTG at various concentrations and analyzed by the developed UPLC-MS method. (A) Cell growth in the first 8 hours after IPTG
induction; (B) Lycopene at 24 h after induction as a function of IPTG concentration; (C) Intracellular DXP concentration at 5 h after induction as a
function of IPTG concentration; (D) Extracellular MEC concentration at 5 h after induction as a function of IPTG concentration; Presented data were
average of triplicates (except duplicates for growth curve) and standard errors were drawn on the plot. The Student’s t-test was used to calculate the
p values.
doi:10.1371/journal.pone.0047513.g003
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Conclusion
In this study, an anion exchange solid phase extraction was
developed to efficiently and selectively purify all the DXP pathway
intermediates from biological samples simultaneously. UPLC-MS
(TOF) was then optimized to reliably quantify the purified
intermediates with good sensitivity. The method allows the direct
monitoring of DXP metabolites in cells for the production of
isoprenoids, an invaluable tool for rational engineering of the
pathway which is currently not available.
Materials and Methods
Bacteria strains and plasmids
E. coli BL21-Gold (DE3) (Stratagen) [E. coli B F2 ompT hsdS
(rB
2 mB
2) dcm+ Tetr gal l(DE3) endA Hte] was used for lycopene
Figure 4. Overexpression of ispG to alleviate efflux of MEC for lycopene production. SIDF: BL21 Gold (DE3) harboring pET-SIDF and
pACLYC; SIDFG: BL21 Gold (DE3) harboring pET-SIDFG and pACLYC. (A) Lycopene production as a function of time; (B) Extracellular MEC
concentration as a function of time; (C) Intracellular MEC concentration as a function of time; (D) Intracellular HMBPP concentration as a function of
time. Presented data were average of triplicates and standard errors were drawn on the plot.
doi:10.1371/journal.pone.0047513.g004
Figure 5. Efflux pumps were not repressed in the strain
overexpressing dxs-idi-ispDF-ispG. Transcription fold change of
efflux pump encoding genes upon ispG overexpression; bcr, mdtJ,
mdtH, mdtA, mdtG, cmr, emrK, emrE, fsr, mdtL and acrA were known
genes encoding E. coli efflux pumps. Transcriptions of the following
efflux pump encoding genes were too low to be accurately quantified
in this study: cusC, macA, mdtK, mdtA, mdtM and emrD. They were
reported not to be expressed in regular aerobic conditions [24].
Presented data were average of triplicates and standard errors were
drawn on the plot.
doi:10.1371/journal.pone.0047513.g005
Figure 6. Analysis of bacteria other than E. coli. Intracellular DXP
pathway intermediates at middle exponential growth phase. Presented
data were average of triplicates and standard errors were drawn on the
plot. C. violaceum: Chromobacterium violaceum; P. aeruginosa :
Pseudomonas aeruginosa; B. subtilis : Bacillus subtilis.
doi:10.1371/journal.pone.0047513.g006
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production with pACLYC [31]. pET-SIDF (named as p20T7MEP
in [3]) was transformed into BL21-Gold (DE3) harboring
pACLYC. IspG was amplified by polymerase chain reaction with
the extracted E. coli genomic DNA. Primers XhoI-RBS-ispG F
and ispG-BamHI R were used (primers used in this study are
summarized in File S6). The purified PCR product was ligated
into pET-SIDF which contained XhoI site and BamHI site. The
resulting plasmid was termed as pET-SIDFG, which was
subsequently transformed into BL21-Gold (DE3) with pACLYC.
E. coli DH5a (Invitrogen) [F- Q80lacZDM15 D(lacZYA-
argF)U169 recA1 endA1 hsdR17(rk2, mk+) phoA supE44 thi-1
gyrA96 relA1 l2] was used for genomic DNA extraction. E. coli
XL10-Gold (Stratagene) [Tetr D(mcrA)183 D(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F9
proAB lacIqZDM15 Tn10 (Tetr) Tn5 (Kanr) Amy]] with pACLYC
was used for production of recombinant ispE enzymes. IspE was
amplified by polymerase chain reaction with the extracted E. coli
genomic DNA. Primers SacI-ispE F and ispE-XhoI R were used
(File S6). The purified PCR product was ligated into a modified
pBAD-B (Invitrogen) which contained six histidine tag, SacI site
and XhoI site. The resulting plasmid was termed as pBAD-ispE,
which was subsequently transformed into E. coli XL10-Gold with
pACLYC.
Wild type Bacillus subtilis (BGSC 1A1) was requested from
BGSC. Wild type Chromobacterium violaceum, Pseudomonas aeruginosa
and Staphylococcus aureus were gifts from Prof. Yew Wen Shan
(Department of Biochemistry, NUS).
Synthesis of CDP-MEP
Standards of all the DXP pathway intermediates are commer-
cially available (Echelon) except CDP-MEP which was synthesized
in house as described in this session. Recombinant ispE was purified
from E. coli XL10-Gold containing pBAD-ispE and pACLYC. A
colony was picked from agar plate, inoculated into 2xPY medium
(20 g/L peptone, 10 g/L yeast extract and 10 g/L NaCl, pH=7)
containing 34 mg/mL chloramphenicol and 100 mg/mL ampicil-
lin, and incubated overnight. Five hundred microliter aliquots of
cell culture grown overnight were inoculated into 25 mL 2xPY
medium in 250 mL shake flask. Cells were grown at 37uC/
300 rpm until OD595 reached between 0.5,1.0. The cells were
then induced with 10 mM L-arabinose and grown at 20uC for
24 hours. The cell pellets were collected and resuspended in 1 mL
B-PER II reagent (Pierce) and homogenized on Mini-Beadbeater-
16 (Biospec) with 200 mL glass beads for 1 min. The cell lysates
were centrifuged for 10 min at 4uC and the supernatant was
diluted with 20 mL NPI-10 (50 mM Na2HPO4, 300 mM NaCl
and 10 mM imidazole, pH=8) and incubated with 200 mg Ni-
NTA micro beads (USB) for 1 h at room temperature. The beads
were washed with 40 mL NPI-10 and eluted with 300 mL NPI-250
(50 mM Na2HPO4, 300 mM NaCl and 250 mM imidazole,
pH=8).
In a 50 mL reaction, 1.25 mM CDP-ME was converted into
CDP-MEP with 10.5 mg recombinant ispE in the presence of
40 mM Tris (pH=6), 2.5 mM MgCl2, 50 mM b-mercaptoetha-
nol and 10 mM ATP. The reaction was incubated at 37uC for
15 h and terminated with 450 mL acidic extraction solution
(acetonitrile/methanol/water 40:40:20+0.1 M formic acid). CDP-
MEP was confirmed by mass spectrometry and the concentration
was estimated by measuring consumed CDP-ME in the reaction.
E. coli growth and induction of protein expression
A colony was picked from agar plate, inoculated into 2xPY
medium containing 34 mg/mL chloramphenicol and 100 mg/mL
ampicillin, and incubated overnight. Fifty microliter aliquots of cell
culture grown overnight were inoculated into 5 mL 2xPY medium
in 50 mL Falcon tube. Cells were grown at 37uC/300 rpm until
OD595 reached between 0.5,1.0. The cells were then induced
with IPTG at the indicated concentrations and grown at 28uC for
the given time periods prior to collection for metabolic extraction
or lycopene assays.
Extraction and quantification of lycopene
Fifty microliters of cell suspension was sampled at 24 h after
induction, and the OD595 was recorded. The cells were
centrifuged for 2 min and resuspended in 200 mL of acetone.
Resuspended cells were vortexed for 10 min and centrifuged at
3,000 g for 2 min. One hundred microliters of supernatant was
mixed with equal volume of ethanol and transferred to 96 well
optical bottom plate (NUNC). Lycopene content was determined
by interpolating from a standard dilution of lycopene (Sigma)
based on absorbance at 472 nm (Spectra Max 190, Molecular
Devices).
Solid phase extraction of the DXP pathway intermediates
in biological samples
Cell suspension equivalent to 6 mL OD595=1.0 cells were
withdrawn. The cells were centrifuged for 5 min. The cell pellets
were resuspended in 10 mL acidic extraction solution (acetonitrile/
methanol/water 40:40:20 +0.1 M formic acid) [32] for intracellular
metabolite extraction. One hundred microliter supernatant was
diluted with 100 mL ddH2O and 800 mL modified acidic extraction
solution (acetonitrile/methanol 50:50 +0.125 M formic acid) for
extracellular metabolite extraction. The resuspended cell pellets in
acidic extraction solution was incubated at 220uC for 60 min with
periodic shaking. Following centrifugation, the supernatant was
purified through a LC-NH2 resin (Sigma). Diluted broth superna-
tant was also purified by LC-NH2 resin in the same way. The
cartridge was eluted with 400 mL 1% NH4OH solution after
centrifugation at 3,000 g for 2 min and pH of eluate was
subsequently adjusted to acidic (pH=5) by 3 mL acetic acid.
UPLC – MS quantification of the DXP pathway
intermediates
A LC-MS/MS method was developed for phosphorylated
sugars with HPLC MS/MS [14]. The method was modified for
Figure 7. The effects of fosmidomycin inhibition of dxr on DXP
metabolism. Twenty five microgram per milliliter fosmidomycin was
used to inhibit MEC biosynthesis at 4 h after induction, and the
metabolites of BL21 Gold (DE3) harboring pET-SIDF and pAC-LYC were
analyzed before and 2 h after inhibition; Presented data were average
of triplicates and standard errors were drawn on the plot.
doi:10.1371/journal.pone.0047513.g007
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DXP intermediates with UPLC (Waters ACQUITY UPLC) –
(TOF)MS (Bruker micrOTOF II) platform. In brief, aqueous
solution containing 15 mM acetic acid and 10 mM tributylamine
and methanol were used as mobile phase with a UPLC C18
column (Waters CSH C18 1.7 mm 2.1650 mm). The elution was
done at 0.15 mL/min (Table 2). Electrospray ionization was used
and mass spectrometry was operated to scan 50–800 m/z in
negative mode with 2500 V end plate voltage and 4500 V
capillary voltage. Nebulizer gas was provided in 1 bar, drying gas
temperature was 9 mL/min, and dry gas temperature was 200uC.
Sample injection volume was 5 mL.
A range of m/z typically with 0.06 m/z width (the average m/z
distribution width with the used MS instrument) was extracted
from the acquired data (50–800 m/z) for each intermediate. The
range of m/z was determined with 50 mM standards of each
intermediate prepared individually in water except CDP-MEP
which was in elution solution of SPE. At the assay condition, all
the intermediates were detected in the form [M-H]2. Retention
time was subsequently determined for each intermediate with the
same 50 mM standards and the set m/z extraction range. The
peak area was calculated with the software provided by the
manufacturer. Based on the peak area, concentrations of the DXP
pathway intermediates were determined from calibration curves
constructed by using synthetic standards prepared in biological
matrix (cell extracts or broth supernatant).
Linearity of the assays was determined with cell extracts
containing DXP, MEP, CDP-ME, CDP-MEP, MEC and
HMBPP in concentration of 2 mM, 1 mM, 0.5 mM, 0.25 mM,
0.1 mM, 0.05 mM, 0.02 mM and 0.01 mM. Intraday/interday
variations were determined with indicated number of replicates
and sample concentration as Table 1.
Transcription quantification
Cell suspension equivalent to 0.1 mL OD595= 1.0 cells was
sampled at 4 h after induction. Gene transcription was quantified
as described in [11], where cysG, idnT and hcaT were used as
reference genes. Primers used were summarized in File S6.
Fosmidomycin inhibition of MEC biosynthesis
Fosmidomycin was added into the cell in the final concentration
of 25 mg/mL at 4 h after the IPTG induction. Intracellular and
extracellular metabolites were analyzed at 2 h after the fosmido-
mycin inhibition.
Growth of bacteria other than E. coli
Glycerol stocks of Bacillus subtilis, Chromobacterium violaceum,
Pseudomonas aeruginosa and Staphylococcus aureus were directly
inoculated into 2xPY and incubated at 37uC overnight. Cell
pellets of cells grown overnight were resuspended in 10 mL 2xPY
(OD595= 0.2) in 50 mL Falcon tube. Cells were grown at 37uC/
300 rpm until OD595 reached between 2 and 3, when cells were
collected for metabolite quantifications.
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